跳转至内容
Merck
  • Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay.

Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay.

Molecular cell (2019-07-14)
Lisa Fish, Albertas Navickas, Bruce Culbertson, Yichen Xu, Hoang C B Nguyen, Steven Zhang, Myles Hochman, Ross Okimoto, Brian D Dill, Henrik Molina, Hamed S Najafabadi, Claudio Alarcón, Davide Ruggero, Hani Goodarzi
摘要

Post-transcriptional regulation of RNA stability is a key step in gene expression control. We describe a regulatory program, mediated by the RNA binding protein TARBP2, that controls RNA stability in the nucleus. TARBP2 binding to pre-mRNAs results in increased intron retention, subsequently leading to targeted degradation of TARBP2-bound transcripts. This is mediated by TARBP2 recruitment of the m6A RNA methylation machinery to its target transcripts, where deposition of m6A marks influences the recruitment of splicing regulators, inhibiting efficient splicing. Interactions between TARBP2 and the nucleoprotein TPR then promote degradation of these TARBP2-bound transcripts by the nuclear exosome. Additionally, analysis of clinical gene expression datasets revealed a functional role for TARBP2 in lung cancer. Using xenograft mouse models, we find that TARBP2 affects tumor growth in the lung and that this is dependent on TARBP2-mediated destabilization of ABCA3 and FOXN3. Finally, we establish ZNF143 as an upstream regulator of TARBP2 expression.